The Latest Cardiac and Vascular News
Ethics Committee Approval is Final Step Prior to Enrollment of Claritas’ Phase 1 Clinical Study of R-107 SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that the Australian Human Research Ethics […]
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN360 significantly lowered Lp(a) in a dose-dependent manner up to 98% with reductions of up to 81% persisting at 150 days Results to be presented in late breaker at the American […]
Company’s reSept™ ASD Occluder Aims to Evolve Septal Closure with its Novel Metal-Free Frame Design BAAR, Switzerland and SANTA CLARA, Calif., Feb. 8, 2022 /PRNewswire/ — atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced it has received approval for the start […]
TEL AVIV, Israel, Feb. 8, 2022 /PRNewswire/ — MedHub, a privately held medical device company focused on improving and simplifying cardiac care by replacing risky and costly invasive procedures with AI image-based tools, today announced that it has successfully secured $1 million bringing the total sum raised to $4.2 million. The round was led by […]
NASHVILLE, Tenn., Feb. 8, 2022 /PRNewswire/ — IVX Health, a national provider of infusion and injection therapy for patients with complex chronic conditions, announced today the expansion of its injection formulary with the addition of Leqvio® (inclisiran), a new FDA-approved therapy by Novartis Pharmaceuticals Corporation indicated for the treatment of adult patients with clinical atherosclerotic cardiovascular disease (ASCVD) […]
VANCOUVER and MINNEAPOLIS, Feb. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation yet again for 2022. […]
– Abbott’s investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart – Proprietary implant-to-implant (i2i™) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate – Aveir DR is also specifically […]
SINGAPORE, Feb. 4, 2022 /PRNewswire/ — Genesis MedTech Group (Genesis or Group) has completed the acquisition of JC Medical (JCM), a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases. The acquisition means that Genesis […]
DUBLIN–(BUSINESS WIRE)–CroíValve, a Dublin based medical device company developing a novel treatment for tricuspid regurgitation, has raised a Series A round to fund a Feasibility clinical study with its DUO Coaptation Valve system. This novel approach to treating tricuspid regurgitation combines the best of repair and replacement to provide the […]
New Research From Included Health Finds Virtual Care With a Holistic Approach Controls Blood Pressure SAN FRANCISCO–(BUSINESS WIRE)–According to a new study published in Mayo Clinic Proceedings: Innovations, Quality & Outcomes, utilizing virtual care visits to manage hypertensive patients demonstrated an improvement in blood pressure in 77 percent of patients. According […]
